STUDIES OF AN AFRICAN POPULATION ENDEMIC FOR HTLV

非洲人群 HTLV 流行病的研究

• 批准号: 3183736
• 负责人: Martin nmi Haas
• 金额: $ 14.07万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-09-30 至 1988-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3183736
• 关键词: Betaherpesvirinae; Epstein Barr virus; Israel; blood tests; cancer risk; enzyme linked immunosorbent assay; ethnic group; genetic mapping; genome; hepatitis B virus group; histopathology; human T cell lymphotropic virus type 1; human T cell lymphotropic virus type 2; human immunodeficiency virus 1; longitudinal human study; lymphoma; medical records; molecular cloning; nucleic acid sequence; parent offspring interaction; serology /serodiagnosis; virus infection mechanism

Our preliminary sero-epidemiologic survey of ethnic groups in Israel has shown that 37% of healthy Falasha individuals ("Black Jews" of Ethopian decent) have antibodies for HTLV-I and -II.* This is the highest known prevalence of antibody to HTLV in any population and indicates widespread infection with HTLV. HTLV is an exogenous virus and is associated with the development of several human malignancies. Sero-epidemiologic studies will be performed to (i) characterize the clinically relevant biologic activities; (ii) detect the exact mode of horizontal transmission of the virus; (iii) study virus-host interactions including determinations of host-range and localization and overlap of different types of HTLV. The hypothesis will be tested that prevalence of HTLV antibodies is correlated with antibodies to other viruses implicated in human malignancy, specifically CMV, EBV, and HBV. A cross-sectional study will be done to confirm the hypothesis that HTLV antibodies are associated with specific T-cell malignancy, and to probe for new and unrecognized disease associations. Prospective studies will test the mode of HTLV transmission of mother to child and will characterize the immune response of neonatal HTLV infection. Absorption enzyme immunoassay studies suggest that sero-positive Falashas carry a new subtype of HTLV that crossreacts with HTLV types I and II but differs from them. HTLV will be isolated from the lymphocytes of seropositive Falasha individuals, grown in culture, and purified in quantity. An ELISA test will be established and competition immunoassays among HTLV types -I, -II, and -Falasha will be performed. HTLV isolated from Falasha individuals will be molelcularly cloned, restriction maps will be derived, and selected regions of the viral genome will be sequenced and compared with other subtypes of the group. * In addition, 10% of these have antibodies to HTLV-III as well.

我们对以色列各族裔群体进行的初步血清流行病学调查 研究表明，37% 的健康法拉沙人（埃塞俄比亚的“黑人犹太人”） 体面）有 HTLV-I 和 -II 抗体。*这是已知最高的 HTLV 抗体在任何人群中普遍存在，表明广泛存在 HTLV 感染。 HTLV是一种外源性病毒，与 几种人类恶性肿瘤的发展。 将进行血清流行病学研究，以 (i) 表征 临床相关的生物活性； (ii) 检测确切的模式 病毒的水平传播； (iii) 研究病毒与宿主的相互作用 包括确定宿主范围和定位以及重叠 不同类型的HTLV。 该假设将得到检验，即 HTLV 抗体与其他相关病毒的抗体相关 人类恶性肿瘤，特别是 CMV、EBV 和 HBV。 横截面 将进行研究以证实 HTLV 抗体是的假设 与特定 T 细胞恶性肿瘤相关，并探索新的和 未被认识的疾病关联。 前瞻性研究将测试该模式 HTLV 母婴传播的影响及其免疫特征 新生儿 HTLV 感染的反应。 吸收酶免疫分析研究表明血清阳性的 Falashas 携带 HTLV 的新亚型，可与 I 型和 II 型 HTLV 发生交叉反应，但 与他们不同。 HTLV将从淋巴细胞中分离出来 血清反应呈阳性的 Falasha 个体，在培养物中生长，并在 数量。 将建立 ELISA 测试和竞争免疫分析 将执行 HTLV 类型 -I、-II 和 -Falasha 之间的操作。 HTLV 隔离 来自法拉沙的个体将被分子克隆，限制性图谱将被 病毒基因组的选定区域将被测序并 与该组的其他亚型相比。 * 此外，其中 10% 还具有 HTLV-III 抗体。